{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:56:34Z","timestamp":1774544194758,"version":"3.50.1"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T00:00:00Z","timestamp":1460937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre Hospitalier Universitaire de Reims","award":["AOL2011"],"award-info":[{"award-number":["AOL2011"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0153635","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T13:33:34Z","timestamp":1460986414000},"page":"e0153635","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-702X","authenticated-orcid":true,"given":"Jean-Philippe","family":"Bertocchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Barbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Lavaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Toupance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Nazeyrollas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,4,18]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.coph.2013.05.004","article-title":"Maintenance immunosuppression in renal transplantation","volume":"13","author":"MC Menon","year":"2013","journal-title":"Current opinion in pharmacology"},{"issue":"24","key":"ref2","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"BJ Nankivell","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"M Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00007890-198707000-00027","article-title":"Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function","volume":"44","author":"J English","year":"1987","journal-title":"Transplantation"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"F Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"B Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"A Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"A McCurley","year":"2012","journal-title":"Nature medicine"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"I Feria","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity","volume":"289","author":"JM Perez-Rojas","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/ndt\/gfn204","article-title":"Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats","volume":"23","author":"FT Nielsen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1470320314561248","article-title":"Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity","volume":"16","author":"QL Sun","year":"2015","journal-title":"Journal of the renin-angiotensin-aldosterone system: JRAAS"},{"key":"ref13","article-title":"Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration","author":"CA Amador","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"P Rossignol","year":"2014","journal-title":"Circulation Heart failure"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"NC Edwards","year":"2012","journal-title":"British journal of clinical pharmacology"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","article-title":"Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months","volume":"42","author":"E Gonzalez Monte","year":"2010","journal-title":"Transplant Proc"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"R Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"AS Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"DN Juurlink","year":"2004","journal-title":"N Engl J Med"},{"issue":"20","key":"ref21","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"AF Hernandez","year":"2012","journal-title":"Jama"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"O Vardeny","year":"2014","journal-title":"Circulation Heart failure"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/00007890-199610270-00025","article-title":"Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage","volume":"62","author":"B Kaplan","year":"1996","journal-title":"Transplantation"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ndt\/gfm864","article-title":"ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations","volume":"23","author":"C Mitterbauer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1523-1755.2004.00627.x","article-title":"Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression","volume":"65","author":"K Hocherl","year":"2004","journal-title":"Kidney Int"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2362.2011.02517.x","article-title":"Cyclosporine metabolic side effects: association with the WNK4 system","volume":"41","author":"S Melnikov","year":"2011","journal-title":"European journal of clinical investigation"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension","volume":"17","author":"EJ Hoorn","year":"2011","journal-title":"Nature medicine"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"C765","DOI":"10.1152\/ajpcell.00528.2007","article-title":"K restriction inhibits protein phosphatase 2B (PP2B) and suppression of PP2B decreases ROMK channel activity in the CCD","volume":"294","author":"Y Zhang","year":"2008","journal-title":"American journal of physiology Cell physiology"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ndt\/gfl714","article-title":"Renal tubular acidosis after kidney transplantation\u2014incidence, risk factors and clinical implications","volume":"22","author":"K Keven","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"ref30","first-page":"245","article-title":"Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect","volume":"25","author":"RA Stahl","year":"1986","journal-title":"Clinical nephrology"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000186520","article-title":"Influence of ciclosporin A on renal tubular function after kidney transplantation","volume":"59","author":"P Heering","year":"1991","journal-title":"Nephron"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ki.1993.38","article-title":"Nephron segment-specific inhibition of Na+\/K(+)-ATPase activity by cyclosporin A","volume":"43","author":"JA Tumlin","year":"1993","journal-title":"Kidney Int"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1067\/mlc.2000.110371","article-title":"Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients","volume":"136","author":"A Henger","year":"2000","journal-title":"J Lab Clin Med"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1681\/ASN.2014020205","article-title":"Current status of bicarbonate in CKD","volume":"26","author":"M Dobre","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"O Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"ref36","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","article-title":"Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles","volume":"16","author":"MI Danjuma","year":"2014","journal-title":"Current hypertension reports"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCHEARTFAILURE.113.000709","article-title":"Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"7","author":"LA Allen","year":"2014","journal-title":"Circulation Heart failure"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/ki.2014.214","article-title":"The relationship between estimated sodium and potassium excretion and subsequent renal outcomes","volume":"86","author":"A Smyth","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"N Khosla","year":"2009","journal-title":"American journal of nephrology"},{"issue":"22","key":"ref41","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"F Zannad","year":"2012","journal-title":"European heart journal"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"JP Bertocchio","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN)","volume":"53","author":"P Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","article-title":"New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone","volume":"293","author":"NA Bobadilla","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/HYPERTENSIONAHA.113.01967","article-title":"Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness","volume":"63","author":"G Galmiche","year":"2014","journal-title":"Hypertension"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Y Matsumoto","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"19","key":"ref47","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","article-title":"Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy","volume":"58","author":"P Rossignol","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"The American journal of cardiology"},{"issue":"8","key":"ref49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"MH Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Y Ito","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"MR Weir","year":"2015","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0153635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T16:32:31Z","timestamp":1567787551000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0153635"}},"subtitle":[],"editor":[{"given":"Christophe","family":"Mariat","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,18]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0153635","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,18]]}}}